Broad Licenses CRISPR/Cas9 IP to GE Healthcare, Sigma-Aldrich | GenomeWeb

NEW YORK (GenomeWeb) – The Broad Institute has granted GE Healthcare and Sigma-Aldrich non-exclusive licenses to intellectual property covering CRISPR/Cas9 for research applications, the companies announced separately today.

Under the arrangements, both companies will have access to the CRISPR IP portfolio, which includes patents related to the use of the gene-editing technology in eukaryotic cells that was pioneered in the lab of Broad researcher Feng Zhang.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.